COMPANY:

Caris Life Sci

"Caris Discovery...today announced a multi-year strategic partnership with Merck KGaA, Darmstadt, Germany, which operates its healthcare business as EMD Serono in the U.S. and Canada, to accelerate the discovery and development of first-in-class antibody-drug conjugates (ADC) for cancer patients....Under the terms of the agreement, Merck KGaA, Darmstadt, Germany, will provide Caris with an upfront payment as well as research funding. In addition, Caris will be eligible for discovery, development, regulatory and sales-based milestone payments that may total up to $1.4 billion along with tiered royalties. Merck KGaA, Darmstadt, Germany will receive an exclusive global license to develop, manufacture and commercialize ADC therapeutics for selected targets."

"Caris Life Sciences® (Caris)...announced that the company and collaborators within the Caris Precision Oncology Alliance™ (POA) will collectively present 10 studies across eight tumor types at the 2024 American Association for Cancer Research (AACR) Annual Meeting on April 5-10, 2024, in San Diego, CA, at Booth Number 1105."

"Caris Life Sciences® (Caris)...announced...that the company and collaborators within the Caris Precision Oncology Alliance™ (POA) will collectively present three studies across multiple gynecological tumor types at the 2024 SGO Annual Meeting on Women’s Cancer, March 16-18, 2024, in San Diego."

"Caris Life Sciences® (Caris)...announced an ongoing collaboration with the Beat Childhood Cancer Research Consortium, a group of over 50 universities and children’s hospitals, based at Penn State College of Medicine in Hershey, Pa., that offers a worldwide network of pediatric cancer clinical trials."

"Caris Life Sciences® (Caris)...announced...that MUSC Hollings Cancer Center has joined the Caris Precision Oncology Alliance™ (POA)...The Caris Precision Oncology Alliance is a growing network of leading cancer centers and research consortia across the globe that collaborate to advance precision oncology and biomarker-driven research, with its members working together to establish and optimize standards of care for molecular testing through innovative research to improve clinical outcomes for all cancer patients."

"Caris Life Sciences...announced that the company and collaborators within the Caris Precision Oncology Alliance (POA) will collectively present eight studies across four tumor types at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, January 25-27, 2024 in San Francisco. The findings demonstrate the continued and expanded capabilities of Caris' comprehensive multi-modal database to enable novel insights into cancer that could have profound effects on a patient's diagnosis, prognosis, care plan and response to treatment."

"Caris Life Sciences^®(Caris)...announced today that the company and collaborators within the Caris Precision Oncology Alliance™ (POA) will collectively present 11 studies across six solid tumor types at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, January 18-20, 2024 in San Francisco. The findings demonstrate the power of Caris' comprehensive multi-modal database to enable novel insights into cancer that could have profound effects on a patient's diagnosis, prognosis, care plan and response to treatment."

"The agreement will allow AbbVie to leverage Caris' expansive real-world, multi-modal database in oncology and ConcertAI's collection of research-grade clinical data across a wide range of cancers, to guide the development of novel therapies for patients most likely to benefit. The agreement will also allow AbbVie to utilize ConcertAI and Caris' clinical network and laboratory capabilities combined with AI/ ML learning to optimize oncology clinical trials and patient enrollment."

"Caris Life Sciences®...and Flatiron Health...announced a partnership to create a multimodal data offering to support and accelerate biopharmaceutical drug development and patient care...Combining the breadth and depth of Caris’ genomic, transcriptomic and imaging database with Flatiron’s industry-leading longitudinal patient data and high-quality clinical outcomes, backed by deep scientific expertise, equips cancer researchers with robust comprehensive real-world data (RWD) offering at scale to power the next wave of cancer therapeutics."

"Caris Life Sciences^®(Caris)...announced that the company and collaborators within the Caris Precision Oncology Alliance™ (POA) will collectively present findings at the San Antonio Breast Cancer Symposium (SABCS) that illustrate the potential impact of molecular profiling on the treatment of breast cancer. The findings demonstrate the power of Caris' comprehensive clinico-genomic database that enables novel insights into cancer that could have profound effects on a patient's diagnosis, prognosis, care plan, and response to treatment. SABCS is being held December 5-9, 2023 (Booth #1433) in San Antonio, Texas."

"Caris Life Sciences® (Caris)...announced...that Atrium Health Levine Cancer, an integrated cancer program that unites cancer services at Atrium Health Levine Cancer Institute and Atrium Health Wake Forest Baptist, has joined the Caris Precision Oncology Alliance™ (POA)...The POA is a growing network of leading cancer centers and research consortia across the globe that collaborate to advance precision oncology and biomarker-driven research, with its members working together to establish and optimize standards of care for molecular testing through innovative research to improve clinical outcomes for cancer patients."

"Pramana, Inc....announced a multi-year agreement with Caris Life Sciences (Caris)...As part of the agreement, Pramana will digitize approximately 1.5 million slides per year with its family of intelligent scanning systems and advanced software, bringing efficiency to digital operations."

"Caris Life Sciences® ...announced...that Sarah Cannon Research Institute (SCRI)...has joined the Caris Precision Oncology Alliance™ (POA)...The POA is a growing network of leading cancer centers and research consortia across the globe that collaborate to advance precision oncology and biomarker-driven research, with its members working together to establish and optimize standards of care for molecular testing through innovative research to improve clinical outcomes for cancer patients."

"Caris Life Sciences^®(Caris)...announced that the company and collaborators within the Caris Precision Oncology Alliance™ (POA) will collectively present seven studies across a breadth of tumor types at the European Society for Medical Oncology (ESMO) Congress 2023 in Madrid, Spain from October 20-24, 2023 (Booth #513)....Data to be presented by Caris and the POA include the results of a molecular analysis of more than 278,000 tumors that indicate potential new therapeutic opportunities in gastrointestinal cancers. Other notable topics explored in these abstracts include a real-world data analysis of gene expression and outcomes in breast cancer, exploration of the tumor-immune microenvironment in lung cancer, and genomic and immune profiling of patients with a rare and aggressive form of eye cancer."

"Caris Life Sciences®...announced...that Loyola University Chicago’s Stritch School of Medicine has joined the Caris Precision Oncology Alliance™ (POA)...The POA is a growing network of leading cancer centers and research consortia across the globe that collaborate to advance precision oncology and biomarker-driven research, with its members working together to establish and optimize standards of care for molecular testing through innovative research to improve clinical outcomes for cancer patients."

"Caris Life Sciences® (Caris)...announced...that UC Davis Comprehensive Cancer Center has joined the Caris Precision Oncology Alliance™ (POA)...The POA is a growing network of leading cancer centers and research consortia across the globe that collaborate to advance precision oncology and biomarker-driven research, with its members working together to establish and optimize standards of care for molecular testing through innovative research to improve clinical outcomes for cancer patients."

"Caris Life Sciences® (Caris)...announced today that NRG Oncology (NRG), a National Cancer Institute (NCI) National Clinical Trials Network (NCTN) cooperative group, has joined the Caris Precision Oncology Alliance™ (POA)...The POA is a growing network of leading cancer centers and research consortia across the globe that collaborate to advance precision oncology and biomarker-driven research, with its members working together to establish and optimize standards of care for molecular testing through innovative research to improve clinical outcomes for cancer patients."

"Caris Life Sciences®...announced...that University Hospitals (UH) Seidman Cancer Center has joined the Caris Precision Oncology Alliance™ (POA). The POA is a growing network of leading cancer centers and research consortia across the globe that collaborate to advance precision oncology and biomarker-driven research, with its members working together to establish and optimize standards of care for molecular testing through innovative research to improve clinical outcomes for cancer patients."

"Caris Life Sciences®...announced...that the Broad Institute of MIT and Harvard has joined the Caris Precision Oncology Alliance™ (POA). As a POA member, the Broad Institute will collaborate with Caris on various precision oncology research projects and signature development."

"Caris Life Sciences...announced today that the Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai), in New York, NY, has joined the Caris Precision Oncology Alliance™ (POA) and will collaborate with Caris on various research projects."

"Caris Life Sciences®...announced...that SWOG Cancer Research Network has joined the Caris Precision Oncology Alliance™ (POA). The POA is a growing network of leading cancer centers and research consortia across the globe that collaborate to advance precision oncology and biomarker-driven research, with its members working together to establish and optimize standards of care for molecular testing through innovative research to improve clinical outcomes for cancer patients."

"Caris Life Sciences® (Caris)...and ConcertAI...announced an expanded translational sciences and clinical development solutions partnership. In the coming months, Caris and ConcertAI will create a prospectively generated, EHR-enabled and contemporaneously matched database of molecular, clinical and multi-modal data that will enable novel insights for precision medicine, therapeutic development and clinical trials management for academic and biopharma researchers."

"Caris Life Sciences® (Caris)...announced...that Memorial Sloan Kettering Cancer Center (MSK), one of the world’s premier cancer centers, has joined the Caris Precision Oncology Alliance™ (POA) and will collaborate with Caris on various research projects...The POA is a growing network of leading cancer centers across the globe that collaborate to advance precision oncology and biomarker-driven research, with its members working together to establish and optimize standards of care for molecular testing through innovative research to improve clinical outcomes for cancer patients."

"Caris Life Sciences® (Caris)...announced that the company and collaborators within the Caris Precision Oncology Alliance™ (POA) will collectively present 42 studies across more than 30 solid tumor types at the 2023 American Society of Clinical Oncology (ASCO®) Annual Meeting from June 2-6, 2023 (Booth #13081). The findings demonstrate the power of Caris’ comprehensive clinico-genomic database that enable novel insights into cancer that could have profound effects on a patient’s diagnosis, prognosis, care plan, and response to treatment."

"Caris Life Sciences®...announced...that Robert H. Lurie Comprehensive Cancer Center of Northwestern University has joined the Caris Precision Oncology Alliance™ (POA). The POA is a growing network of leading cancer centers across the globe that collaborate to advance precision oncology and biomarker-driven research, with its members working together to establish and optimize standards of care for molecular testing through innovative research to improve clinical outcomes for cancer patients."

"Caris Life Sciences® (Caris)...announced...that Yale Cancer Center has joined the Caris Precision Oncology Alliance™ (POA). The POA is a growing network of leading cancer centers across the globe that collaborate to advance precision oncology and biomarker-driven research. POA members work together to establish and optimize standards of care for molecular testing through innovative research to improve clinical outcomes for cancer patients."

"Caris Life Sciences®...announced...that the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) has joined the Caris Precision Oncology Alliance™ (POA). The POA is a growing network of leading cancer centers across the globe that collaborate to advance precision oncology and biomarker-driven research. POA members work together to establish and optimize standards of care for molecular testing through innovative research to improve clinical outcomes for cancer patients."

"Caris Life Sciences® (Caris)...announced...that CARTI Cancer Center has joined the Caris Precision Oncology Alliance™ (POA). The POA is a growing network of leading cancer centers across the globe that collaborate to advance precision oncology and biomarker-driven research. POA members work together to establish and optimize standards of care for molecular testing through innovative research to improve clinical outcomes for cancer patients."

"Caris Life Sciences®...announced that the company and partners within the Caris Precision Oncology Alliance™ (POA) will collectively present four studies across 14 tumor types at the 2023 American Association for Cancer Research (AACR) Annual Meeting being held April 14-19, 2023 in Orlando, Florida, at Booth Number 130."

"Caris Life Sciences®...and Flare Therapeutics...announced a multi-year strategic collaboration to accelerate precision medicine approaches across five of Flare’s therapeutic programs into clinical trials through advanced molecular profiling approaches that guide patient selection and participation...The partnership reinforces Flare’s commitment to longitudinal testing, leveraging Caris’ comprehensive molecular tissue and liquid profiling services including whole exome sequencing and whole transcriptome sequencing for patients enrolled in Flare’s clinical trials, while also applying Caris’ data and analytics tools to bolster future clinical trial enrollment programs and companion diagnostics capabilities."

"Caris Life Sciences®...announced...that the University of Chicago (UChicago) Medicine Comprehensive Cancer Center has joined the Caris Precision Oncology Alliance™ (POA). The POA is a growing network of leading cancer centers across the globe that collaborate to advance precision oncology and biomarker-driven research. POA members work together to establish and optimize standards of care for molecular testing through innovative research focused on predictive and prognostic markers that improve the clinical outcomes for cancer patients."

"Caris Life Sciences^®(Caris)...announced a strategic research partnership with Incyte Corporation...to augment precision medicine approaches for Incyte's oncology pipeline....Under the terms of the agreement, Incyte will leverage Caris' data insights and analytics capabilities to discover novel biomarkers and optimize clinical positioning strategies for its oncology programs. For drug candidates developed under the collaboration, patients enrolled in Incyte-led clinical trials will undergo longitudinal testing with Caris' comprehensive tissue and liquid molecular profiling assays. Incyte will also leverage Caris' biomarker-driven patient selection for clinical trials including options to partner on developing companion diagnostics for programs in the partnership."

"Caris Life Sciences^®...announced that the company and partners within the Caris Precision Oncology Alliance™ (POA) will collectively present five studies across three tumor types at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, February 16-18, 2023 in San Francisco (Tabletop #50)."

"Caris Life Sciences®...announced...that the UCI Health Chao Family Comprehensive Cancer Center has joined the Caris Precision Oncology Alliance™ (POA). The POA is a growing network of leading cancer centers across the globe that collaborate to advance precision oncology and biomarker-driven research. POA members work together to establish and optimize standards of care for molecular testing through innovative research focused on predictive and prognostic markers that improve the clinical outcomes for cancer patients."

"Caris Life Sciences®...announced that the company and partners within the Caris Precision Oncology Alliance™ (POA) will collectively present 18 studies across more than six tumor types at the 2023 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, January 19-21, 2023 in San Francisco...large number of collaborative abstracts accepted for presentation at ASCO GI, demonstrating the power of Caris’ comprehensive molecular profiling and the large-scale collaboration between POA sites..."

"Singapore-based therapeutics developer Juniper Biologics said...that it has been granted distribution rights for Caris Life Sciences' molecular profiling services in Southeast Asia...Caris' comprehensive molecular profiling services include whole-exome and transcriptome sequencing to guide the use of molecularly targeted therapies."

"Caris Life Sciences^®...announced an expansion of their collaboration to research, develop and commercialize novel XmAb^® bispecific and multi-specific antibodies directed against novel targets, identified and proposed by Caris, for the treatment of patients with cancer. Building upon the initial August 2022 agreement, this expanded collaboration will increase the number of targets and cancer types that Caris will interrogate with its proprietary, multi-omics discovery engine platform, Caris Discovery....Under the terms of the new agreement, Xencor will receive exclusive worldwide rights to research, develop and commercialize products directed to up to three targets discovered under the collaboration. Caris will receive an upfront payment and will be eligible to receive up to $187 million in development and commercial milestone payments."

"This retrospective study aimed to use real-world data to determine the prevalence and clinical significance of estrogen receptor (ER) loss in invasive lobular carcinoma (ILC). Results demonstrate that, based on analysis of a large real-world dataset of over 20,000 patients with advanced breast cancer, ER-loss occurs in around one in ten ILC patients and has poor prognostic implications compared to ILC without ER loss or invasive ductal carcinoma with ER-loss. Genomic analysis also revealed significant differences between breast cancer patients with ER-loss who responded to treatment and those who did not."

"Caris Life Sciences...and Hummingbird Bioscience...today announced a strategic collaboration to advance clinical development of Hummingbird Bioscience's anti-HER3 therapy, HMBD-001....Leveraging Caris' extensive real-world clinico-genomic database to support clinical trial design, Hummingbird Bioscience will be better able to prospectively identify patients with molecular biomarkers that are potentially associated with response to HMBD-001."

"Caris Life Sciences® (Caris)...announced today that Cleveland Clinic Cancer Center has joined Caris’ Precision Oncology Alliance™ (POA). The POA is a growing network of leading cancer centers across the globe that collaborate to advance precision oncology and biomarker-driven research. POA members work together to establish and optimize standards of care for molecular testing through innovative precision medicine focused research that improve the clinical outcomes for cancer patients."

"Caris Life Sciences® (Caris)...announced...that University of Iowa Holden Comprehensive Cancer Center has joined Caris’ Precision Oncology Alliance™ (POA). The POA is a growing network of leading cancer centers across the globe that collaborate to advance precision oncology and biomarker-driven research. POA members work together to establish and optimize standards of care for molecular testing through innovative research focused on predictive and prognostic markers that improve the clinical outcomes for cancer patients."

"Everything Genetic said...that it will distribute Caris Life Sciences' Molecular Intelligence Tumor Seek service in the UK...Everything Genetic is based in Nantwich, an English city equidistant between Liverpool and Birmingham, and will be the sole distributor of Caris' MI Tumor Seek service in the UK."